Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Passes Food Safety Law Following Melamine Infant Formula Disasters

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's top legislature passed the long-awaited Food Safety Law in response to a national call for stricter food safety following the Sanlu dairy melamine incident, which led to the deaths of six infants last year (PharmAsia News, Jan. 5, 2009)

You may also be interested in...



China FDA Highlights Product Recalls, Manufacturers Urged To Make Rapid Responses

Despite being one of the largest medical product markets in the world, China has seen few product recalls. The situation could be changing however as China FDA has requested drug and device manufacturers to quickly withdraw products that have deficiencies and potential safety risks.

China FDA Highlights Product Recalls, Manufacturers Urged To Make Rapid Responses

Despite being one of the largest medical product markets in the world, China has seen few product recalls. The situation could be changing however as China FDA has requested drug and device manufacturers to quickly withdraw products that have deficiencies and potential safety risks.

Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition

With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.

Related Content

Latest News
UsernamePublicRestriction

Register

SC071233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel